Avoro Capital Advisors LLC Increases Stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Avoro Capital Advisors LLC grew its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 14.4% during the 4th quarter, Holdings Channel reports. The fund owned 5,150,000 shares of the company’s stock after buying an additional 650,000 shares during the quarter. Kymera Therapeutics comprises about 2.9% of Avoro Capital Advisors LLC’s holdings, making the stock its 14th biggest position. Avoro Capital Advisors LLC owned approximately 0.08% of Kymera Therapeutics worth $207,184,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Wellington Management Group LLP lifted its position in Kymera Therapeutics by 14.9% in the fourth quarter. Wellington Management Group LLP now owns 5,307,326 shares of the company’s stock valued at $213,514,000 after purchasing an additional 688,967 shares during the period. Vanguard Group Inc. increased its position in Kymera Therapeutics by 2.8% during the 4th quarter. Vanguard Group Inc. now owns 4,887,312 shares of the company’s stock worth $196,617,000 after purchasing an additional 133,546 shares during the period. Geode Capital Management LLC raised its stake in shares of Kymera Therapeutics by 5.0% during the 4th quarter. Geode Capital Management LLC now owns 1,105,487 shares of the company’s stock worth $44,484,000 after buying an additional 52,263 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Kymera Therapeutics by 5.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 387,187 shares of the company’s stock valued at $15,577,000 after buying an additional 20,346 shares during the period. Finally, First Trust Advisors LP boosted its stake in shares of Kymera Therapeutics by 43.2% in the fourth quarter. First Trust Advisors LP now owns 176,220 shares of the company’s stock valued at $7,089,000 after buying an additional 53,175 shares in the last quarter.

Insider Buying and Selling

In other news, COO Jeremy G. Chadwick sold 1,383 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $42,112.35. Following the transaction, the chief operating officer now directly owns 67,800 shares in the company, valued at $2,064,510. This represents a 2.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Bruce N. Jacobs sold 7,035 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $214,215.75. Following the completion of the sale, the chief financial officer now owns 201,886 shares of the company’s stock, valued at approximately $6,147,428.70. The trade was a 3.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 10,659 shares of company stock worth $324,567. 15.82% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of brokerages have recently issued reports on KYMR. HC Wainwright increased their price target on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the company a “buy” rating in a report on Friday, February 28th. Citigroup initiated coverage on Kymera Therapeutics in a research note on Thursday, March 13th. They set a “buy” rating and a $52.00 price target on the stock. Stephens reaffirmed an “overweight” rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a research note on Tuesday, January 21st. Finally, Leerink Partners reiterated an “outperform” rating and set a $60.00 target price on shares of Kymera Therapeutics in a research report on Friday, December 27th. Three investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Kymera Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $56.36.

Kymera Therapeutics Stock Performance

Shares of KYMR opened at $25.97 on Monday. Kymera Therapeutics, Inc. has a 1 year low of $19.45 and a 1 year high of $53.27. The company’s 50 day simple moving average is $30.47 and its 200 day simple moving average is $38.97. The company has a market capitalization of $1.69 billion, a price-to-earnings ratio of -11.10 and a beta of 2.22.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.12). The business had revenue of $7.39 million for the quarter, compared to analysts’ expectations of $14.81 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. Equities analysts expect that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.